| Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 … MV Mateos, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, ... The lancet haematology 7 (5), e370-e380, 2020 | 206 | 2020 |
| Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ... Blood advances 1 (23), 2105-2114, 2017 | 189 | 2017 |
| Percutaneous absorption of trihalomethanes, haloacetic acids, and haloketones X Xu, TM Mariano, JD Laskin, CP Weisel Toxicology and Applied Pharmacology 184 (1), 19-26, 2002 | 177 | 2002 |
| Selective detection of monohydroxy metabolites of polycyclic aromatic hydrocarbons in urine using liquid chromatography/triple quadrupole tandem mass spectrometry X Xu, J Zhang, L Zhang, W Liu, CP Weisel Rapid Communications in Mass Spectrometry 18 (19), 2299-2308, 2004 | 128 | 2004 |
| Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography–tandem mass spectrometry X Xu, MM Iba, CP Weisel Clinical Chemistry 50 (12), 2323-2330, 2004 | 126 | 2004 |
| Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency RJ Auchus, EO Buschur, AY Chang, GD Hammer, C Ramm, D Madrigal, ... The Journal of Clinical Endocrinology & Metabolism 99 (8), 2763-2770, 2014 | 86 | 2014 |
| Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment PL Clemens, X Yan, HM Lokhorst, S Lonial, N Losic, I Khan, R Jansson, ... Clinical pharmacokinetics 56, 915-924, 2017 | 76 | 2017 |
| Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate–treated castration-resistant prostate cancer patients XS Xu, CJ Ryan, K Stuyckens, MR Smith, F Saad, TW Griffin, YC Park, ... Clinical Cancer Research 21 (14), 3170-3177, 2015 | 72 | 2015 |
| Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ... Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017 | 67 | 2017 |
| Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact XS Xu, M Yuan, MO Karlsson, A Dunne, P Nandy, A Vermeulen The AAPS journal 14, 927-936, 2012 | 63 | 2012 |
| Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes XS Xu, K Moore, P Burton, K Stuyckens, W Mueck, S Rossenu, ... British journal of clinical pharmacology 74 (1), 86-97, 2012 | 61 | 2012 |
| Stratification of population in NHANES 2009–2014 based on exposure pattern of lead, cadmium, mercury, and arsenic and their association with cardiovascular, renal and … X Yao, XS Xu, Y Yang, Z Zhu, Z Zhu, F Tao, M Yuan Environment International 149, 106410, 2021 | 59 | 2021 |
| A Bayesian population PBPK model for multiroute chloroform exposure Y Yang, X Xu, PG Georgopoulos Journal of exposure science & environmental epidemiology 20 (4), 326-341, 2010 | 53 | 2010 |
| Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer K Stuyckens, F Saad, XS Xu, CJ Ryan, MR Smith, TW Griffin, MK Yu, ... Clinical pharmacokinetics 53, 1149-1160, 2014 | 50 | 2014 |
| Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain XS Xu, JW Smit, R Lin, K Stuyckens, R Terlinden, P Nandy Clinical pharmacokinetics 49, 671-682, 2010 | 43 | 2010 |
| Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models XS Xu, A Dunne, H Kimko, P Nandy, A Vermeulen Journal of pharmacokinetics and pharmacodynamics 38, 423-432, 2011 | 38 | 2011 |
| Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma X Yan, PL Clemens, T Puchalski, S Lonial, H Lokhorst, PM Voorhees, ... Clinical pharmacokinetics 57, 529-538, 2018 | 28 | 2018 |
| Pharmacokinetics and exposure–response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma XS Xu, MA Dimopoulos, P Sonneveld, PJ Ho, A Belch, M Leiba, M Capra, ... Advances in therapy 35, 1859-1872, 2018 | 27 | 2018 |
| Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR XS Xu, M Etropolski, D Upmalis, A Okamoto, R Lin, P Nandy Pharmaceutical research 29, 2555-2564, 2012 | 26 | 2012 |
| Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries XS Xu, MN Samtani, A Dunne, P Nandy, A Vermeulen, F De Ridder, ... Journal of pharmacokinetics and pharmacodynamics 40, 537-544, 2013 | 24 | 2013 |
